This channel includes news on cardiovascular care delivery, including how patients are diagnosed and treated, cardiac care guidelines, policies or legislation impacting patient care, device recalls that may impact patient care, and cardiology practice management.
Burnout remains one of the biggest issues in modern healthcare. More than 1,500 surgeons, including many from the field of cardiac surgery, provided feedback for a new report on that very topic.
Oversizing transcatheter heart valves can improve TAVR outcomes. There is still a reason to be cautious, however, especially when patients are receiving a balloon-expandable valve.
The brain is the single most complex internal system in the body. That’s a no-brainer. But can you name the runner-up? (Bonus points for guessing what this has to do with healthcare AI.)
Two medical charities that last year gave $640 million to 200,000 struggling Americans are combining forces so they can expand their collective wherewithal.
Researchers: “Clinicians’ perceptions about older patients’ interest in and ability to use mobile health apps may negatively impact recommendation of mHealth apps and subsequent adoption by older adults.”
The latest COVID-19 vaccine began entering recipients’ bodies last September. Now comes early CDC data supporting the formulation’s general effectiveness.
Researchers explored the potential of an alternate way to perform PFA on patients with persistent AFib, presenting their findings live at AF Symposium 2024 in Boston.
The approval, based on positive results from the TRISCEND II trial, represents a significant milestone for the treatment of severe tricuspid regurgitation.
Heart teams have several options when patients present with stable chest pain and require further testing. According to a brand new analysis of nearly 800 patients, CCTA may be the best place to start.
The nonprofit patient-safety organization says the list “reflects our judgment about which risks should be given attention now to help care providers, as well as device manufacturers, prioritize their patient safety efforts.”
The FDA’s final decision was based largely on positive results from the ADVENT clinical trial, which compared treatment with the Farapulse PFA System to the current standard of care.
Annual SAVR volumes in the United States decreased by a whopping 44.5% from 2012 to 2022. However, heart teams across the country seem to agree that surgery is a safer, more effective treatment option than TAVR when patients present with bicuspid aortic valves.